$14.12
2.54%
Nasdaq, Fri, Oct 02 2026.
ISIN
US0080641071
Symbol
AVTE

Aerovate Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Aerovate Therapeutics Inc Classifications & Recommendation

Buy
94%
Hold
6%

Aerovate Therapeutics Inc Price Target

Target Price $47.94
Price $14.12
Potential
Number of Estimates 11
11 Analysts have issued a price target Aerovate Therapeutics Inc 2027 . The average Aerovate Therapeutics Inc target price is $47.94. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 16 Analysts recommend Aerovate Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Aerovate Therapeutics Inc stock has an average upside potential 2027 of . Most analysts recommend the Aerovate Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -3.19 -2.93
96.26% 8.15%
P/E negative

12 Analysts have issued a Aerovate Therapeutics Inc forecast for earnings per share. The average Aerovate Therapeutics Inc EPS is

$-2.93
unlock
. This is
42.93% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-2.39 16.59%
unlock
, the lowest is
$-3.18 55.12%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-3.19 96.26%
2026
$-2.93 8.15%
unlock
2027
$-2.98 1.71%
unlock
2028
$-2.92 2.01%
unlock

P/E ratio

Current -6.89 60.82%
2026
-4.82 30.02%
unlock
2027
-4.73 1.87%
unlock
2028
-4.83 2.11%
unlock

Current Aerovate Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wedbush
Locked
➜
Locked
Locked Aug 11 2026
BTIG
Locked
➜
Locked
Locked Aug 10 2026
UBS
Locked
➜
Locked
Locked Jun 15 2026
Wedbush
Locked
➜
Locked
Locked Jun 02 2026
BTIG
Locked
➜
Locked
Locked Jun 01 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Jun 01 2026
BTIG
Locked
➜
Locked
Locked May 27 2026
Analyst Rating Date
Locked
Wedbush:
Locked
➜
Locked
Aug 11 2026
Locked
BTIG:
Locked
➜
Locked
Aug 10 2026
Locked
UBS:
Locked
➜
Locked
Jun 15 2026
Locked
Wedbush:
Locked
➜
Locked
Jun 02 2026
Locked
BTIG:
Locked
➜
Locked
Jun 01 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jun 01 2026
Locked
BTIG:
Locked
➜
Locked
May 27 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today